मूलभूत आँकड़े
| CIK | 1873093 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to CytoMed Therapeutics Limited
SEC Filings (Chronological Order)
यह पृष्ठ SEC फाइलिंग की एक पूरी, कालानुक्रमिक सूची प्रदान करता है, ओनरशिप फाइलिंग को छोड़कर, जो हम अन्यत्र प्रदान करते हैं।
| August 28, 2025 |
Exhibit 99.1 Update on recent acquisition - CytoMed Therapeutics expands into auto-immune diseases building on its recent cord blood bank acquisition Singapore, Singapore – (August 28, 2025) – CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable |
|
| August 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File Number: 001-41677 CytoMed Therapeutics Limited (Registrant’s Name) 1 Commonwealth Lane #08-22 Singapore 149544 (Address of Principal Executive Offices) Indicate by c |
|
| August 19, 2025 |
CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program Exhibit 99.1 CytoMed Therapeutics Limited Announces At-the-Market (ATM) Offering Program SINGAPORE, August 18, 2025 — CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor blood-derived, cell-based allogeneic therapies for the affordable treatment of |
|
| August 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2025 Commission File No. 001-41677 CytoMed Therapeutics limited (Translation of registrant’s name into English) 1 Commonwealth Lane #08-22 Singapore 149544 (Address of principal executiv |
|
| August 19, 2025 |
CYTOMED therapeutics limited ORDINARY SHARES SALES AGREEMENT Exhibit 10.1 CYTOMED therapeutics limited ORDINARY SHARES SALES AGREEMENT August 18, 2025 R.F. Lafferty & Co., Inc. 40 Wall Street, 29th Floor New York, NY 10005 Ladies and Gentlemen: CytoMed Therapeutics Limited, a company incorporated in Singapore, having its registered office at Puglisi & Associates, 850 Library Ave., Suite 204, Newark, DE 19711 (the “Company”), confirms its agreement (this “Ag |
|
| August 18, 2025 |
Up to U.S.$4,304,945 Ordinary Shares CytoMed Therapeutics Limited Filed pursuant to Rule 424(b)(5) File No. 333-288033 PROSPECTUS SUPPLEMENT (To Prospectus dated June 23, 2025) Up to U.S.$4,304,945 Ordinary Shares CytoMed Therapeutics Limited We have entered into an ATM Sales Agreement (the “Sales Agreement”) with R.F. Lafferty & Co., Inc. (“Lafferty” or the “Sales Agent”), dated August 18, 2025, relating to the sale of our ordinary shares offered by this prospe |
|
| July 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-41677 CytoMed Therapeutics Limited (Exact name of registrant as specified in its charter) 1 Commonwealth Lane #08-22 Singapore 149544 (Address of Principal |
|
| July 21, 2025 |
Exhibit 99.1 Update On Clinical Trial Milestone - CytoMed Therapeutics Achieves Completion of Dose Level 1 of its ANGELICA TRIAL, and Proceeding to Dose Level 2 in Patients with Advanced Solid Tumors or Haematological Malignancies SINGAPORE, July 21, 2025 — Further to our announcement filed on Form 6-K on November 20, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Si |
|
| July 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025. Commission File Number: 001-41677 CytoMed Therapeutics Limited (Exact name of registrant as specified in its charter) 1 Commonwealth Lane #08-22 Singapore 149544 (Address of Principa |
|
| July 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2025 Commission File Number: 001-41677 CytoMed THerapeutics Limited (Translation of registrant’s name into English) 1 Commonwealth Lane #08-22 Singapore 149544 (Address of principal execut |
|
| June 20, 2025 |
CytoMed Therapeutics Limited 1 Commonwealth Lane Singapore 149544 CytoMed Therapeutics Limited 1 Commonwealth Lane #08-22 Singapore 149544 June 20, 2025 VIA EDGAR Division of Corporation Finance Office of Life Sciences U. |
|
| June 13, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form F-3 (Form Type) CYTOMED THERAPEUTICS LIMITED (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price (3) Fee Rate Amount of |
|
| June 13, 2025 |
CYTOMED THERAPEUTICS LIMITED FORM OF SENIOR INDENTURE Dated as of [ ], 20[ ] [ ] TABLE OF CONTENTS Exhibit 4.2 CYTOMED THERAPEUTICS LIMITED FORM OF SENIOR INDENTURE Dated as of [ ], 20[ ] [ ] Trustee TABLE OF CONTENTS PAGE ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 SECTION 1.01. Definitions. 1 SECTION 1.02. Other Definitions. 5 SECTION 1.03. Incorporation by Reference of Trust Indenture Act. 5 SECTION 1.04. Rules of Construction. 6 ARTICLE II THE SECURITIES 6 SECTION 2.01. Issuable |
|
| June 13, 2025 |
Exhibit 4.3 CYTOMED THERAPEUTICS LIMITED FORM OF SUBORDINATED INDENTURE Dated as of [ ], 20[ ] [ ] Trustee TABLE OF CONTENTS PAGE ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 SECTION 1.01. Definitions. 1 SECTION 1.02. Other Definitions. 5 SECTION 1.03. Incorporation by Reference of Trust Indenture Act. 5 SECTION 1.04. Rules of Construction. 6 ARTICLE II THE SECURITIES 6 SECTION 2.01. Iss |
|
| June 13, 2025 |
As filed with the U.S. Securities and Exchange Commission on June 13, 2025 As filed with the U.S. Securities and Exchange Commission on June 13, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM F-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CYTOMED THERAPEUTICS LIMITED (Exact name of registrant as specified in its charter) Singapore 2834 Not Applicable (State or other jurisdiction of incorporation or organ |
|
| May 16, 2025 |
Exhibit 99.2 Control Number: Number of Shares: Registered Shareholder: CytoMed Therapeutics Limited 1 Commonwealth Lane, #08-22 Singapore 149544. PROXY Solicited on Behalf of the Board of Directors for the Annual General Meeting of Shareholders on June 26, 2025, at 12:00 P.M., Singapore time (June 26, 2025, at 12:00 A.M., Eastern Time) The undersigned hereby appoints Choo Chee Kong as proxy with f |
|
| May 16, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2025 Commission File Number: 001-41677 CytoMed Therapeutics Limited (Exact name of registrant as specified in its charter) 1 Commonwealth Lane #08-22 Singapore 149544 (Address of principal |
|
| May 16, 2025 |
Exhibit 99.1 CytoMed Therapeutics Limited 1 Commonwealth Lane #08-22 Singapore 149544 PROXY STATEMENT AND NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To the shareholders of May 16, 2025 CytoMed Therapeutics Limited Singapore To our shareholders: It is my pleasure to invite you to our Annual General Meeting of Shareholders of CytoMed Therapeutics Limited (the “Company”) on June 26, 2025, at 12 |
|
| April 28, 2025 |
Exhibit 12.1 Certification by the Principal Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Choo Chee Kong, Chairman and Director of CytoMed Therapeutics Limited (the “Company”), certify that: 1. I have reviewed this annual report on Form 20-F of the Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to sta |
|
| April 28, 2025 |
Consent of Independent Registered Public Accounting Firm Exhibit 15.1 Consent of Independent Registered Public Accounting Firm We hereby consent to the incorporation by reference in the Registration Statement on Form S-8, as amended (File No. 333-284145) of our report dated April 28, 2025 with respect to the consolidated statements of financial positions of CytoMed Therapeutics Limited and its subsidiaries (collectively the “Company”) as of December 31, |
|
| April 28, 2025 |
Exhibit 12.2 Certification by the Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 I, Yvonne Goh, Chief Financial Officer of CytoMed Therapeutics Limited (the “Company”), certify that: 1. I have reviewed this annual report on Form 20-F of the Company; 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state |
|
| April 28, 2025 |
Exhibit 13.1 Certification by the Principal Executive Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 I, Choo Chee Kong, Chairman and Director of CytoMed Therapeutics Limited (the “Company”), hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: a. the Company’s annual report on |
|
| April 28, 2025 |
Exhibit 99.1 CytoMed Therapeutics Reports Full Year Ended December 31, 2024 Financial Results and Provides Clinical and Corporate Updates Singapore – (April 28, 2025) – CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived, cell |
|
| April 28, 2025 |
Exhibit 2.1 Description of the Registrant’s Securities Registered under Section 12 of the Securities Exchange Act of 1934, as Amended (the “Exchange Act”) Ordinary Shares, no par value per share (“Ordinary Shares”), of Cytomed Therapeutics Limited (“we,” “our,” “our company,” or “us”) are listed and traded on the Nasdaq Capital Market under the symbol “GDTC”, and in connection with this listing (b |
|
| April 28, 2025 |
Exhibit 13.2 Certification by the Principal Financial Officer Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 I, Yvonne Goh, Chief Financial Officer of CytoMed Therapeutics Limited (the “Company”), hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of my knowledge: a. the Company’s annual report on Fo |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 28, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2025 Commission File Number: 001-41677 CytoMed Therapeutics Limited (Exact name of registrant as specified in its charter) 1 Commonwealth Lane #08-22 Singapore 149544 (Address of Principa |
|
| January 6, 2025 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 CytoMed Therapeutics signs Business & Research Collaboration Agreement with India’s SunAct Cancer Institute Private Limited to advance use of allogeneic off-the-shelf Gamma Delta T Cells for treatment of solid cancers in a proposed Phase 2 clinical trial in India Singapore – (January 6, 2025) – CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), |
|
| January 6, 2025 |
CytoMed Therapeutics Limited 2023 EQUITY INCENTIVE PLAN EX-10.1 3 ex10-1.htm Exhibit 10.1 CytoMed Therapeutics Limited 2023 EQUITY INCENTIVE PLAN 1. Purpose. The purposes of this Plan are: (a) to attract and retain the best available personnel for positions of substantial responsibility, (b) to provide additional incentives to Employees, Directors, and Consultants (including members of the Company’s Scientific Advisory Board), and (c) to promote the su |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CYTOMED THERAPEUTICS LIMITED (Exact Name of Registrant as Specified in its Charter) Singapore N/A (State or Other Jurisdiction of Incorporation or Organization) (I.R.S. Employer Identification No.) 1 Commonwealth Lane #08-22 Singapore 149544 (Address of Principal |
|
| January 6, 2025 |
Exhibit 107 Calculation of Filing Fee Tables S-8 (Form Type) CytoMed Therapeutics Ltd (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Share (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Ordinary Shares, no par value Rule 457(c) and (h) 1,279,117 $ 3. |
|
| January 6, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2025 Commission File Number: 001-41677 CytoMed Therapeutics Limited (Exact name of registrant as specified in its charter) 1 Commonwealth Lane #08-22 Singapore 149544 (Address of Princi |
|
| December 5, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of December 2024 Commission File Number: 001-41677 CytoMed Therapeutics Limited (Exact name of registrant as specified in its charter) 1 Commonwealth Lane #08-22 Singapore 149544 (Address of Princ |
|
| November 20, 2024 |
Exhibit 99.1 Update on Clinical Milestone - CytoMed Therapeutics Announces First Patient Dosed in its First-in-Human Phase I Clinical Trial of Allogeneic CAR-Gamma Delta T Cell Therapy in Patients with Advanced Solid Tumours or Haematological Malignancies SINGAPORE, November 20 2024 — Further to an announcement on October 7, 2024, CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company” |
|
| November 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of November 2024 Commission File Number: 001-41677 CytoMed Therapeutics Limited (Exact name of registrant as specified in its charter) 1 Commonwealth Lane #08-22 Singapore 149544 (Address of Princ |
|
| October 7, 2024 |
Exhibit 99.1 CytoMed Therapeutics’ first-in-human Phase I ANGELICA clinical trial using its patented donor allogeneic chimeric antigen receptor T cell (CAR-T cell) against blood and solid tumors received co-funding support from the NMRC Clinical Trial Grant Completion of cash acquisition of licenced cord blood bank expanding CytoMed’s strategy to cord blood-derived biologics through its subsidiary |
|
| October 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-41677 CytoMed Therapeutics Limited (Exact name of registrant as specified in its charter) 1 Commonwealth Lane #08-22 Singapore 149544 (Address of Princi |
|
| October 3, 2024 |
Exhibit 99.1 CytoMed Therapeutics completes cash acquisition of Cord Blood Banking Licence and Assets expanding CytoMed’s strategy to cord blood-derived biologics through subsidiary, LongevityBank SINGAPORE, October 3, 2024 — CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develo |
|
| October 3, 2024 |
Exhibit 99.2 THIS AGREEMENT IS MADE THIS 6TH DAY F MAY 2024 BETWEEN CELLSAFE INTERNATIONAL SDN BHD (IN LIQUIDATION) (REGISTRATION NO. 200601028503 (748259-P) (“VENDOR”) AND IPSC DEPOSITORY SDN BHD (REGISTRATION NO. 201901022718 (1332047-T)) (“PURCHASER”) MASTER AGREEMENT This MASTER AGREEMENT is made this 06 day of May 2024 BETWEEN: (1) CELLSAFE INTERNATIONAL SDN BHD (IN LIQUIDATION) (Registration |
|
| October 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of October 2024 Commission File Number: 001-41677 CytoMed Therapeutics Limited (Exact name of registrant as specified in its charter) 1 Commonwealth Lane #08-22 Singapore 149544 (Address of Princi |
|
| September 30, 2024 |
Exhibit 99.3 CytoMed Therapeutics Reports Six Months Ended June 30, 2024 Financial Results and Provides Clinical and Corporate Updates Conference call via Zoom is scheduled for October 8, 2024 at 9 a.m. ET (9 p.m. SGT) https://us06web.zoom.us/meeting/register/tZMrcOmppj0sGdA37lASywTyixRflo9w1TZT Singapore – (September 30, 2024) – CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”) |
|
| September 30, 2024 |
Exhibit 99.1 CYTOMED THERAPEUTICS LIMITED AND SUBSIDIARIES UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS INDEX Page Unaudited Interim Condensed Consolidated Statements of Profit or Loss and Other Comprehensive Loss for the Six months ended June 30, 2023 and 2024 1 Unaudited Interim Condensed Consolidated Statements of Financial Positions as of December 31, 2023 and June 30, 2024 2 |
|
| September 30, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Financial Period Ended 30 Jun 2024 Commission File Number: 001-41677 CytoMed Therapeutics Limited (Exact name of registrant as specified in its charter) 1 Commonwealth Lane #08-22 Singapore 149544 (Addr |
|
| September 30, 2024 |
Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE SIX MONTHS ENDED JUNE 30, 2024 The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the unaudited interim condensed consolidated financial statements and the notes thereto, included as Exhibit 99.1 to this Report on Form |
|
| June 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-41677 CytoMed Therapeutics Limited (Exact name of registrant as specified in its charter) 1 Commonwealth Lane #08-22 Singapore 149544 (Address of Princip |
|
| June 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of June 2024 Commission File Number: 001-41677 CytoMed Therapeutics Limited (Exact name of registrant as specified in its charter) 1 Commonwealth Lane #08-22 Singapore 149544 (Address of Principal |
|
| May 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of May 2024. Commission File Number: 001-41677 CytoMed Therapeutics Limited (Exact name of registrant as specified in its charter) 1 Commonwealth Lane #08-22 Singapore 149544 (Address of Principal |
|
| May 23, 2024 |
GDTC / CytoMed Therapeutics Limited / Choo Chee Kong Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* CytoMed Therapeutics Limited Ordinary Shares, of no par value per share Y1R80M106 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☐ Rule 13d-1(c) ☒ Rule 13d-1(d) * The remainder of this cover page |
|
| April 25, 2024 |
6-K/A 1 form6-ka.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K/A REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-41677 CytoMed Therapeutics Limited (Exact name of registrant as specified in its charter) 1 Commonwealth Lane #08-22 Singapore 1495 |
|
| April 25, 2024 |
Exhibit 99.1 CytoMed Therapeutics Limited 1 Commonwealth Lane #08-22 Singapore 149544 PROXY STATEMENT AND NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To the shareholders of April 25, 2024 CytoMed Therapeutics Limited Singapore To our shareholders: It is my pleasure to invite you to our Annual General Meeting of Shareholders of CytoMed Therapeutics Limited (the “Company”) on May 15, 2024, at 1 |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2024 Commission File Number: 001-41677 CytoMed Therapeutics Limited (Exact name of registrant as specified in its charter) 1 Commonwealth Lane #08-22 Singapore 149544 (Address of Principa |
|
| April 24, 2024 |
Exhibit 99.1 CytoMed Therapeutics Limited 1 Commonwealth Lane #08-22 Singapore 149544 PROXY STATEMENT AND NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS To the shareholders of April 19, 2024 CytoMed Therapeutics Limited Singapore To our shareholders: It is my pleasure to invite you to our Annual General Meeting of Shareholders of CytoMed Therapeutics Limited (the “Company”) on May 15, 2024, at 1 |
|
| April 22, 2024 |
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER Exhibit 12.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER I, CHOO Chee Kong, Chairman and Director of CytoMed Therapeutics Limited (the “Company”) certify that: 1. I have reviewed this annual report on Form 20-F of the Company (this “report”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statem |
|
| April 22, 2024 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the annual report of CytoMed Therapeutics Limited (the “Company”) on Form 20-F for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, GOH Yvonne, Chief Financial Officer of th |
|
| April 22, 2024 |
CYTOMED THERAPEUTICS LIMITED CLAWBACK POLICY Exhibit 97.1 CYTOMED THERAPEUTICS LIMITED CLAWBACK POLICY OVERVIEW In accordance with the applicable rules (the “Nasdaq Rules”) of The Nasdaq Stock Market (“Nasdaq”), Section 10D and Rule 10D-1 (“Rule 10D-1”) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Board of Directors (the “Board”) of CytoMed Therapeutics Limited (the “Company”) has adopted this Policy (the “Pol |
|
| April 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| April 22, 2024 |
CERTIFICATION OF CHIEF FINANCIAL OFFICER Exhibit 12.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER I, GOH Yvonne, Chief Financial Officer of CytoMed Therapeutics Limited (the “Company”) certify that: 1. I have reviewed this annual report on Form 20-F of the Company (this “report”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements m |
|
| April 22, 2024 |
Insider Trading Compliance Manual CytoMed Therapeutics Limited Adopted: November 16, 2023 Exhibit 11.2 Insider Trading Compliance Manual CytoMed Therapeutics Limited Adopted: November 16, 2023 In order to take an active role in the prevention of insider trading violations by its officers, directors, employees, consultants, attorneys, advisors and other related individuals, the Board of Directors (the “Board”) of CytoMed Therapeutics Limited, a Singapore company (the “Company”), has ado |
|
| April 22, 2024 |
DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12(b) OF THE SECURITES EXCHANGE ACT OF 1934 Exhibit 2.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12(b) OF THE SECURITES EXCHANGE ACT OF 1934 CytoMed Therapeutics Limited (the “Company”, “CytoMed”, “we”, “us” and “our”) has the following single class of securities registered under Section 12(b) of the Securities Exchange Act of 1934 (the “Exchange Act”): Title of class Trading Symbol Name of exchange on which registered Ordinary sh |
|
| April 22, 2024 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the annual report of CytoMed Therapeutics Limited (the “Company”) on Form 20-F for the year ended December 31, 2023, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, CHOO Chee Kong, Chairman and Director of |
|
| March 18, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-41677 CytoMed Therapeutics Limited (Exact name of registrant as specified in its charter) 1 Commonwealth Lane #08-22 Singapore 149544 (Address of Principa |
|
| March 18, 2024 |
Exhibit 99.1 CytoMed Therapeutics to Launch Complimentary Cell Banking for Qualified Shareholders for Future Precision Therapies SINGAPORE, March 18, 2024 — CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel blood donor-derived, cell-based allogeneic therapies for the |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of March 2024 Commission File Number: 001-41677 CytoMed Therapeutics Limited (Exact name of registrant as specified in its charter) 1 Commonwealth Lane #08-22 Singapore 149544 (Address of Principa |
|
| March 4, 2024 |
Exhibit 99.1 CytoMed Therapeutics Limited Announces Research Collaboration with Singapore Sengkang General Hospital to Advance Injectable Umbilical Cord-Derived Mesenchymal Stem Cells for Cartilage Diseases and Repair CytoMed diversifies into regenerative medicine SINGAPORE, March 4, 2024 - CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical co |
|
| February 14, 2024 |
GDTC / CytoMed Therapeutics Limited / Choo Chee Kong Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CytoMed Therapeutics Limited Ordinary Shares, of no par value per share Y1R80M106 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☐ Rule 13d-1(c) ☒ Rule 13d-1(d) * The remainder of this cover page |
|
| February 14, 2024 |
GDTC / CytoMed Therapeutics Limited / Zeng Jieming Passive Investment SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CytoMed Therapeutics Limited Ordinary Shares, of no par value per share Y1R80M106 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☐ Rule 13d-1(c) ☒ Rule 13d-1(d) * The remain |
|
| February 14, 2024 |
GDTC / CytoMed Therapeutics Limited / mDR Ltd Passive Investment SC 13G 1 formsc13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CytoMed Therapeutics Limited Ordinary Shares, of no par value per share Y1R80M106 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☐ Rule 13d-1(c) ☒ Rule 13d-1(d) * The remain |
|
| February 14, 2024 |
GDTC / CytoMed Therapeutics Limited / Wang Shu Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* CytoMed Therapeutics Limited Ordinary Shares, of no par value per share Y1R80M106 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☐ Rule 13d-1(b) ☐ Rule 13d-1(c) ☒ Rule 13d-1(d) * The remainder of this cover page |
|
| January 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of January 2024 Commission File Number: 001-41677 CytoMed Therapeutics Limited (Exact name of registrant as specified in its charter) 1 Commonwealth Lane #08-22 Singapore 149544 (Address of Princi |
|
| January 29, 2024 |
Exhibit 99.1 Malaysian Patent Granted for CytoMed Therapeutics’ Licensed Allogeneic CAR-Gamma Delta T Cell Technology The Company now has exclusive rights to a Malaysia, US and China patent. Singapore, Singapore – (January 29, 2024) – CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies |
|
| November 17, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the Financial Period Ended 30 Jun 2023 Commission File Number: 001-41677 CytoMed Therapeutics Limited (Exact name of registrant as specified in its charter) 1 Commonwealth Lane #08-22 Singapore 149544 (Addr |
|
| November 17, 2023 |
Exhibit 99.3 CytoMed Therapeutics Reports First Half 2023 Financial Report and Provides Corporate Update Conference call webcast is scheduled for November 22 at 9 a.m. ET. Singapore, Singapore – (November 17, 2023) – CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel d |
|
| November 17, 2023 |
Exhibit 99.1 CYTOMED THERAPEUTICS LIMITED AND SUBSIDIARIES UNAUDITED INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS INDEX Page Unaudited Interim Condensed Consolidated Statements of Profit or Loss and Other Comprehensive Loss for the Six Months Ended June 30, 2022 and 2023 1 Unaudited Interim Condensed Consolidated Statements of Financial Positions as of December 31, 2022 and June 30, 2023 2 |
|
| November 17, 2023 |
Exhibit 99.2 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS FOR THE SIX MONTHS ENDED JUNE 30, 2023 The following discussion and analysis of our financial condition and results of operations should be read in conjunction with the unaudited interim condensed consolidated financial statements and the notes thereto, included as Exhibit 99.1 to this Report on Form |
|
| September 25, 2023 |
Chinese Patent Granted for CytoMed Therapeutics’ Licensed iPSC-based Technology Exhibit 99.1 Chinese Patent Granted for CytoMed Therapeutics’ Licensed iPSC-based Technology Singapore, Singapore – (September 25, 2023) – CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor-derived cell-based allogeneic immunotherapies for the treatment of variou |
|
| September 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of September 2023 Commission File Number: 001-41677 CytoMed Therapeutics Limited (Exact name of registrant as specified in its charter) 1 Commonwealth Lane #08-22 Singapore 149544 (Address of Prin |
|
| August 1, 2023 |
Exhibit 99.1 Chinese Patent Granted for A*STAR Spinoff, CytoMed Therapeutics’ Licensed Allogeneic CAR-Gamma Delta T Cell Technology The Company now has exclusive rights to a US and Chinese patent. Singapore, Singapore – (August 1, 2023) – CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technolog |
|
| August 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of August 2023 Commission File Number: 001-41677 CytoMed Therapeutics Limited (Exact name of registrant as specified in its charter) 1 Commonwealth Lane #08-22 Singapore 149544 (Address of Princip |
|
| July 6, 2023 |
Exhibit 99.1 A*STAR Spinoff CytoMed Therapeutics Announce a Patent for its Licensed CAR-Gamma Delta T Cell Technology Has Been Granted in the US Singapore, July 6, 2023 – CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or “Company”), a Singapore-based biopharmaceutical company focused on harnessing its proprietary technologies to develop novel donor cell-based immunotherapies for the treatm |
|
| July 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of July 2023 Commission File Number: 001-41677 CytoMed Therapeutics Limited (Exact name of registrant as specified in its charter) 1 Commonwealth Lane #08-22 Singapore 149544 (Address of Principal |
|
| May 19, 2023 |
EX-1 2 ex1.htm Exhibit 1 Form of Lock-Up Agreement , 2023 The Benchmark Company, LLC 150 E. 58th Street, 17th Floor New York, NY 10155 As Representative of the several Underwriters named on Schedule 1 to the Underwriting Agreement referenced below. Ladies and Gentlemen: The undersigned understands that The Benchmark Company, LLC (the “Representative”), proposes to enter into an Underwriting Agreem |
|
| May 19, 2023 |
GDTC / CytoMed Therapeutics Ltd / Zeng Jieming Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* CytoMed Therapeutics Limited (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) Y1R80M106 (CUSIP Number) Zeng Jieming c/o 1 Commonwealth Lane #08-22 Singapore 149544 +65 6250 7738 (Name, Address and Telephone Number of Person Au |
|
| May 1, 2023 |
Rule13a-14(a)/15d-14(a) Certification of Principal Executive Officer Exhibit 12.1 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER I, CHOO Chee Kong, Chairman and Director of CytoMed Therapeutics Limited (the “Company”) certify that: 1. I have reviewed this annual report on Form 20-F of the Company (this “report”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statem |
|
| May 1, 2023 |
Exhibit 13.2 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the annual report of CytoMed Therapeutics Limited (the “Company”) on Form 20-F for the year ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Yvonne GOH, Chief Financial Officer of th |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 20-F (Mark One) ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXC |
|
| May 1, 2023 |
Exhibit 13.1 CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 In connection with the annual report of CytoMed Therapeutics Limited (the “Company”) on Form 20-F for the year ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, CHOO Chee Kong, Chairman and Director of |
|
| May 1, 2023 |
Rule 13a-14(a)/15d-14(a) Certification of the Chief Financial Officer Exhibit 12.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER I, Yvonne GOH, Chief Financial Officer of CytoMed Therapeutics Limited (the “Company”) certify that: 1. I have reviewed this annual report on Form 20-F of the Company (this “report”); 2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements m |
|
| May 1, 2023 |
Description of Securities registered under Section 12(b) of the Securities Exchange Act of 1934 Exhibit 2.1 DESCRIPTION OF SECURITIES REGISTERED UNDER SECTION 12(b) OF THE SECURITES EXCHANGE ACT OF 1934 CytoMed Therapeutics Limited (the “Company”, “CytoMed”, “we”, “us” and “our”) has the following single class of securities registered under Section 12(b) of the Securities Exchange Act of 1934 (the “Exchange Act”): Title of class Trading Symbol Name of exchange on which registered Ordinary sh |
|
| April 24, 2023 |
GDTC / CytoMed Therapeutics Ltd / mDR Ltd Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED CytoMed Therapeutics Limited (Name of Issuer) Ordinary Shares, of no par value per share (Title of Class of Securities) Y1R80M106 (CUSIP Number) April 14, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the ru |
|
| April 21, 2023 |
Exhibit 2 Form of Lock-Up Agreement , 2023 The Benchmark Company, LLC 150 E. 58th Street, 17th Floor New York, NY 10155 As Representative of the several Underwriters named on Schedule 1 to the Underwriting Agreement referenced below. Ladies and Gentlemen: The undersigned understands that The Benchmark Company, LLC (the “Representative”), proposes to enter into an Underwriting Agreement (the “Under |
|
| April 21, 2023 |
EX-1 2 ex1.htm Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, each of the undersigned hereby agrees to the joint filing on behalf of each of them of a statement on Schedule 13D (including amendments thereto) with respect to the ordinary shares no par value of CytoMed Therapeutics Limited. Each of the undersigned acknowledges |
|
| April 21, 2023 |
GDTC / CytoMed Therapeutics Ltd / Choo Chee Kong Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* CytoMed Therapeutics Limited (Name of Issuer) Ordinary Shares, no par value (Title of Class of Securities) Y1R80M106 (CUSIP Number) Choo Chee Kong c/o 1 Commonwealth Lane #08-22 Singapore 149544 +65 6250 7738 (Name, Address and Telephone Number of Person |
|
| April 18, 2023 |
Exhibit 1.1 UNDERWRITING AGREEMENT between CYTOMED THERAPEUTICS LIMITED and THE BENCHMARK COMPANY, LLC as Representative of the Several Underwriters CYTOMED THERAPEUTICS LIMITED UNDERWRITING AGREEMENT New York, New York April 13, 2023 The Benchmark Company, LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 150 E. 58th Street, 17th Floor New York, NY 10155 Ladies |
|
| April 18, 2023 |
Form of Representative’s Warrant Exhibit 4.1 Form of Representative’s Warrant Agreement THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER OR ASSIGN THIS PURCHASE WARRANT EXCEPT AS HEREIN PROVIDED AND THE REGISTERED HOLDER OF THIS PURCHASE WARRANT AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEDGE OR HYPOTHECATE THIS PURCHASE WARRANT FOR A PERIOD OF ONE HUNDRED EIGH |
|
| April 18, 2023 |
Cytomed Therapeutics Limited Announces Pricing of Initial Public Offering Exhibit 99.1 Cytomed Therapeutics Limited Announces Pricing of Initial Public Offering Singapore - April 13, 2023 — CytoMed Therapeutics Limited (“CytoMed” or the “Company”), a pre-clinical biopharmaceutical company focused on harnessing its licensed proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers, today announced the pricing of its initial pu |
|
| April 18, 2023 |
Exhibit 99.2 CytoMed Therapeutics Limited Announces Closing of US$9,649,476 Firm Commitment Initial Public Offering Singapore, April 18, 2023 /PRNewswire/ — CytoMed Therapeutics Limited (“CytoMed” or the “Company”) (Nasdaq: GDTC ), a pre-clinical biopharmaceutical company focused on developing novel cell-based immunotherapies for the treatment of human cancers, today announced the closing of its f |
|
| April 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 For the month of April 2023 Commission File Number: 001-41677 CytoMed Therapeutics Limited (Registrant’s Name) 1 Commonwealth Lane #08-22 Singapore 149544 (Address of Principal Executive Offices) Indicate by ch |
|
| April 17, 2023 |
2,412,369 ORDINARY SHARES CYTOMED THERAPEUTICS LIMITED Filed Pursuant to Rule 424(b)(4) Registration No. 333-268456 PROSPECTUS 2,412,369 ORDINARY SHARES CYTOMED THERAPEUTICS LIMITED We are offering ordinary shares. This is the initial public offering of ordinary shares of CytoMed Therapeutics Limited. We are offering, on a firm commitment basis, 2,412,369 ordinary shares. The offering price of our ordinary shares in this offering is U.S.$4.00 per shar |
|
| March 31, 2023 |
CytoMed Therapeutics Limited 1 Commonwealth Lane #08-22 Singapore 149544 CytoMed Therapeutics Limited 1 Commonwealth Lane #08-22 Singapore 149544 March 31, 2023 VIA EDGAR U. |
|
| March 31, 2023 |
CytoMed Therapeutics Limited 1 Commonwealth Lane Singapore 149544 +65 6250 7738 CytoMed Therapeutics Limited 1 Commonwealth Lane #08-22 Singapore 149544 +65 6250 7738 VIA EDGAR March 31, 2023 U. |
|
| March 31, 2023 | ||
| March 31, 2023 |
CORRESP 1 filename1.htm March 31, 2023 Via EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, NE Washington, D.C. 20549 Attn: Tracie Mariner Re: CytoMed Therapeutics Limited (the “Company”) Registration Statement on Form F-1 File No. 333-268456 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended (the “Act”), The Benchma |
|
| March 30, 2023 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 CytoMed Therapeutics Limited (Exact Name of Registrant as Specified in Its Charter) Singapore Not Applicable (State of Incorporation or Organization) (I.R.S. Employer Identification No.) 1 Commonwealth La |
|
| March 30, 2023 |
Opinion of Zaid Ibrahim & Co, regarding certain Malaysian law matters Exhibit 5.3 |
|
| March 30, 2023 |
CytoMed Therapeutics Limited 1 Commonwealth Lane Singapore 149544 +65 6250 7738 CytoMed Therapeutics Limited 1 Commonwealth Lane #08-22 Singapore 149544 +65 6250 7738 VIA EDGAR March 30, 2023 U. |
|
| March 30, 2023 |
As filed with the U.S. Securities and Exchange Commission on March 30, 2023 As filed with the U.S. Securities and Exchange Commission on March 30, 2023 Registration No. 333-268456 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 5 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CytoMed Therapeutics Limited (Exact Name of Registrant as Specified in its Charter) Not Applicable (Translation of Registrant’s name into En |
|
| March 28, 2023 |
Exhibit 10.23 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential INVESTIGATOR-INITIATED CLINICAL STUDY AGREEMENT This Clinical Study Agreement is entered into on 10 March 2023 (“Effective Date”) by and betw |
|
| March 28, 2023 |
As filed with the U.S. Securities and Exchange Commission on March 27, 2023 F-1/A 1 formf-1a.htm As filed with the U.S. Securities and Exchange Commission on March 27, 2023 Registration No. 333-268456 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 4 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CytoMed Therapeutics Limited (Exact Name of Registrant as Specified in its Charter) Not Applicable (Translation of Regi |
|
| March 28, 2023 |
Form of Underwriters’ Warrant (included in Exhibit 1.1) EX-1.1 2 ex1-1.htm Exhibit 1.1 UNDERWRITING AGREEMENT between CYTOMED THERAPEUTICS LIMITED and THE BENCHMARK COMPANY, LLC as Representative of the Several Underwriters CYTOMED THERAPEUTICS LIMITED UNDERWRITING AGREEMENT New York, New York [●], 2023 The Benchmark Company, LLC As Representative of the several Underwriters named on Schedule 1 attached hereto 150 E. 58th Street, 17th Floor New York, N |
|
| March 28, 2023 |
Opinion of Zaid Ibrahim & Co, regarding certain Malaysian law matters Exhibit 5.3 |
|
| March 16, 2023 |
Letter in Lieu of Consent of WWC, P.C., an independent registered public accounting firm Exhibit 15.1 To the Board of Directors and Shareholders of CytoMed Therapeutics Limited LETTER IN LIEU OF CONSENT FOR REVIEW REPORT We have reviewed, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the unaudited interim condensed consolidated financial statements of CytoMed Therapeutics Limited and its subsidiaries for the periods ended June 30, 2 |
|
| March 16, 2023 |
Power of Attorney (included in the signature page to this registration statement) As filed with the U.S. Securities and Exchange Commission on March 15, 2023 Registration No. 333-268456 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CytoMed Therapeutics Limited (Exact Name of Registrant as Specified in its Charter) Not Applicable (Translation of Registrant’s name into En |
|
| March 15, 2023 |
CytoMed Therapeutics Limited 1 Commonwealth Lane Singapore 149544 +65 6250 7738 CORRESP 1 filename1.htm CytoMed Therapeutics Limited 1 Commonwealth Lane #08-22 Singapore 149544 +65 6250 7738 VIA EDGAR March 15, 2023 U.S. Securities & Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attn: Tracie Mariner Re: CytoMed Therapeutics Limited (f/k/a CytoMed Therapeutics Pte. Ltd.) Amendment No. 2 to Registration State |
|
| February 27, 2023 | ||
| February 21, 2023 |
CytoMed Therapeutics Limited 1 Commonwealth Lane Singapore 149544 +65 6250 7738 CORRESP 1 filename1.htm CytoMed Therapeutics Limited 1 Commonwealth Lane #08-22 Singapore 149544 +65 6250 7738 VIA EDGAR February 21, 2023 U.S. Securities & Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attn: Tracie Mariner Re: CytoMed Therapeutics Limited (f/k/a CytoMed Therapeutics Pte. Ltd.) Amendment No.1 to Registration Sta |
|
| February 21, 2023 |
As filed with the U.S. Securities and Exchange Commission on February 21, 2023 As filed with the U.S. Securities and Exchange Commission on February 21, 2023 Registration No. 333-268456 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CytoMed Therapeutics Limited (Exact Name of Registrant as Specified in its Charter) Not Applicable (Translation of Registrant’s name into |
|
| February 21, 2023 |
Letter in Lieu of Consent of WWC, P.C., an independent registered public accounting firm EXHIBIT 15.1 To the Board of Directors and Shareholders of CytoMed Therapeutics Limited LETTER IN LIEU OF CONSENT FOR REVIEW REPORT We have reviewed, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the unaudited interim condensed consolidated financial statements of CytoMed Therapeutics Limited and its subsidiaries for the six months ended June 30 |
|
| February 1, 2023 |
Exhibit 99.4 Consent to be Named as a Director Nominee In connection with the filing by CytoMed Therapeutics Limited of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of CytoMed T |
|
| February 1, 2023 |
Calculation of Registration Fee EX-FILING FEES 24 ex107.htm Exhibit 107 Calculation of Filing Fee Tables Form F-1 (Form Type) CytoMed Therapeutics Limited (Exact Name of Registrant as Specified in its Charter) Not Applicable (Translation of Registrant’s Name into English) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered Proposed Maximum Offerin |
|
| February 1, 2023 |
Letter in Lieu of Consent of WWC, P.C., an independent registered public accounting firm EXHIBIT 15.1 To the Board of Directors and Shareholders of CytoMed Therapeutics Limited LETTER IN LIEU OF CONSENT FOR REVIEW REPORT We have reviewed, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the unaudited interim condensed consolidated financial statements of CytoMed Therapeutics Limited and its subsidiaries for the periods ended June 30, 2 |
|
| February 1, 2023 |
Exhibit 10.14 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential DATED 10 DEC 2019 BETWEEN CYTOMED THERAPEUTICS PTE. LTD. (THE “BORROWER”) AND MDR LIMITED (THE “LENDER”) CONVERTIBLE LOAN AGREEMENT Dentons R |
|
| February 1, 2023 |
Exhibit 99.6 Consent to be Named as a Director Nominee In connection with the filing by CytoMed Therapeutics Limited of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of CytoMed T |
|
| February 1, 2023 |
Constitution of CytoMed Therapeutics Limited Exhibit 3.2 |
|
| February 1, 2023 |
EX-10.22 11 ex10-22.htm Exhibit 10.22 3 January 2023 CYTOMED THERAPEUTICS PTE LTD 21 Bukit Batok Crescent #17-80 WCEGA Tower Singapore 658065 Dear Sirs, CONVERTIBLE LOAN AGREEMENT — Supplemental Agreement No. 3 1. We refer to the Convertible Loan Agreement dated 10 December 2019 entered between you as the Borrower and us as the Lender as amended to date (the “Agreement”), and our subsequent mutual |
|
| February 1, 2023 |
Exhibit 99.2 Consent to be Named as a Director Nominee In connection with the filing by CytoMed Therapeutics Limited of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of CytoMed T |
|
| February 1, 2023 |
Exhibit 10.20 31 December 2021 CYTOMED THERAPEUTICS PTE LTD 21 Bukit Batok Crescent #17-80 WCEGA Tower Singapore 658065 Dear Sirs, CONVERTIBLE LOAN AGREEMENT — Supplemental Agreement No. 1 1. We refer to the Convertible Loan Agreement dated 10 December 2019 entered between you as the Borrower and us as the Lender (the “Agreement”), and our subsequent mutual discussions. 2. Unless otherwise defined |
|
| February 1, 2023 |
Exhibit 99.5 Consent to be Named as a Director Nominee In connection with the filing by CytoMed Therapeutics Limited of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of CytoMed T |
|
| February 1, 2023 |
Exhibit 99.1 Consent to be Named as a Director Nominee In connection with the filing by CytoMed Therapeutics Limited of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of CytoMed T |
|
| February 1, 2023 |
Exhibit 10.21 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential 3 January 2022 CYTOMED THERAPEUTICS PTE LTD 21 Bukit Batok Crescent #17-80 WCEGA Tower Singapore 658065 Dear Sirs, CONVERTIBLE LOAN AGREEMENT |
|
| February 1, 2023 |
Form of Independent Director Appointment Letter Exhibit 10.18 Date: Dear Independent Director Appointment Letter This letter contains the terms for your appointment as an Independent Director of CytoMed Therapeutics Limited incorporated in Singapore (Company No. 201808327H) with registered address at #08-22 One Commonwealth, 1 Commonwealth Lane, Singapore 149544 (the “Company”), the proposed listing vehicle on the US NASDAQ Capital Market (“Nat |
|
| February 1, 2023 |
EX-10.1 5 ex10-1.htm Exhibit 10.1 CytoMed Therapeutics Limited 2023 EQUITY INCENTIVE PLAN 1. Purpose. The purposes of this Plan are: (a) to attract and retain the best available personnel for positions of substantial responsibility, (b) to provide additional incentives to Employees, Directors, and Consultants (including members of the Company’s Scientific Advisory Board), and (c) to promote the su |
|
| February 1, 2023 |
EX-99.7 20 ex99-7.htm Exhibit 99.7 Consent to be Named as a Director Nominee In connection with the filing by CytoMed Therapeutics Limited of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of |
|
| February 1, 2023 |
Form of Nominating and Corporate Governance Committee Charter EX-99.10 23 ex99-10.htm Exhibit 99.10 NOMINATING AND CORPORATE GOVERNANCE COMMITTEE CHARTER OF CYTOMED THERAPEUTICS LIMITED The responsibilities and powers of this Nominating and Corporate Governance Committee (the “Committee”) as delegated by the Board of Directors (the “Board”) of CytoMed Therapeutics Limited (the “Company”) are set forth in this charter. Whenever the Committee takes an action, |
|
| February 1, 2023 |
Specimen Ordinary Share Certificate Exhibit 4.1 |
|
| February 1, 2023 |
As filed with the U.S. Securities and Exchange Commission on January 31, 2023 As filed with the U.S. Securities and Exchange Commission on January 31, 2023 Registration No. 333-268456 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CytoMed Therapeutics Limited (Exact Name of Registrant as Specified in its Charter) Not Applicable (Translation of Registrant’s name into |
|
| February 1, 2023 |
Form of Compensation Committee Charter Exhibit 99.9 COMPENSATION COMMITTEE CHARTER OF CYTOMED THERAPEUTICS LIMITED I. PURPOSES The Compensation Committee (the “Committee”) is appointed by the Board of Directors (the “Board”) of CytoMed Therapeutics Limited (the “Company”) for the purposes of, among other things, (a) discharging the Board’s responsibilities relating to the compensation of the Company’s chief executive officer (the “CEO” |
|
| February 1, 2023 |
Form of Audit Committee Charter Exhibit 99.8 AUDIT COMMITTEE CHARTER OF CYTOMED THERAPEUTICS LIMITED Purpose The Audit Committee (the “Committee”) is appointed by the Board of Directors (the “Board”) of CytoMed Therapeutics Limited (the “Company”) to assist the Board in monitoring (1) the integrity of the annual and other financial statements of the Company, (2) the independent auditor’s qualifications and independence, (3) the |
|
| February 1, 2023 |
Exhibit 99.3 Consent to be Named as a Director Nominee In connection with the filing by CytoMed Therapeutics Limited of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of CytoMed T |
|
| February 1, 2023 |
Form of Executive Director Service Agreement Exhibit 10.19 THIS AGREEMENT is made on the day of 2023 BETWEEN (1) CYTOMED THERAPEUTICS LIMITED (Company Registration No. 201808327H), a company incorporated in Singapore and having its registered address at #08-22 One Commonwealth, 1 Commonwealth Lane, Singapore 149544 (the “Company”); AND (2) (NRIC No. ), a citizen whose residential address is at (the “Executive”), (collectively the “Parties” a |
|
| January 31, 2023 |
CytoMed Therapeutics Limited 1 Commonwealth Lane Singapore 149544 +65 6250 7738 CORRESP 1 filename1.htm CytoMed Therapeutics Limited 1 Commonwealth Lane #08-22 Singapore 149544 +65 6250 7738 VIA EDGAR January 31, 2023 U.S. Securities & Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attn: Tracie Mariner Re: CytoMed Therapeutics Limited (f/k/a CytoMed Therapeutics Pte. Ltd.) Registration Statement on Form F-1 |
|
| November 18, 2022 |
EX-10.4 6 ex10-4.htm Exhibit 10.4 ADDENDUM TO LICENCE AGREEMENT THIS AGREEMENT is made the 1st day of Dec 2020 (“Effective Date”) Between ACCELERATE TECHNOLOGIES PTE LTD, f.k.a.EXPLOIT TECHNOLOGIES PTE LTD (Co. Reg. No. 1995053187D), a company incorporated in Singapore and having its place of business at 1 Fusionopolis Way, #19-00 Connexis North, Singapore 138632 (hereinafter referred to as “A*cce |
|
| November 18, 2022 |
Code of Business Conduct and Ethics EX-14.1 20 ex14-1.htm Exhibit 14.1 CODE OF BUSINESS CONDUCT AND ETHICS 1. Introduction The Board of Directors of CytoMed Therapeutics Pte. Ltd. has adopted this code of business conduct and ethics (the “Code”), which is applicable to all directors, officers and employees, to: ● promote honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest between pe |
|
| November 18, 2022 |
EX-10.11 13 ex10-11.htm Exhibit 10.11 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. THIS SUPPLEMENTAL AGREEMENT is made on 20 January 2021 BETWEEN: (1) Landmark Medical Centre Sdn Bhd (registration no |
|
| November 18, 2022 |
As filed with the U.S. Securities and Exchange Commission on November 18, 2022 As filed with the U.S. Securities and Exchange Commission on November 18, 2022 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 CytoMed Therapeutics Pte. Ltd. (Exact Name of Registrant as Specified in its Charter) Not Applicable (Translation of Registrant?s name into English) Singapore 283 |
|
| November 18, 2022 |
Form of Compensation Committee Charter Exhibit 99.9 FORM OF COMPENSATION COMMITTEE CHARTER OF CYTOMED THERAPEUTICS PTE. LTD. I. PURPOSES The Compensation Committee (the ?Committee?) is appointed by the Board of Directors (the ?Board?) of CytoMed Therapeutics Pte. Ltd. (the ?Company?) for the purposes of, among other things, (a) discharging the Board?s responsibilities relating to the compensation of the Company?s chief executive office |
|
| November 18, 2022 |
Exhibit 10.1 CytoMed Therapeutics Pte. Ltd. 2022 EQUITY INCENTIVE PLAN 1. Purpose. The purposes of this Plan are: (a) to attract and retain the best available personnel for positions of substantial responsibility, (b) to provide additional incentives to Employees, Directors, and Consultants (including members of the Company?s Scientific Advisory Board), and (c) to promote the success of the Compan |
|
| November 18, 2022 |
Form of Nominating and Corporate Governance Committee Charter Exhibit 99.10 FORM OF NOMINATING AND CORPORATE GOVERNANCE COMMITTEE CHARTER OF CYTOMED THERAPEUTICS PTE. LTD. The responsibilities and powers of this Nominating and Corporate Governance Committee (the ?Committee?) as delegated by the Board of Directors (the ?Board?) of CytoMed Therapeutics Pte. Ltd. (the ?Company?) are set forth in this charter. Whenever the Committee takes an action, it shall exe |
|
| November 18, 2022 |
EX-10.13 15 ex10-13.htm Exhibit 10.13 |
|
| November 18, 2022 |
CytoMed Therapeutics Pte. Ltd. 1 Commonwealth Lane Singapore 149544 +65 6250 7738 CORRESP 1 filename1.htm CytoMed Therapeutics Pte. Ltd. 1 Commonwealth Lane #08-22 Singapore 149544 +65 6250 7738 VIA EDGAR November 18, 2022 U.S. Securities & Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attn: Tracie Mariner Re: CytoMed Therapeutics Pte. Ltd. Amendment No. 3 to Draft Registration Statement on Form F-1 Submitted |
|
| November 18, 2022 |
Put Option Agreement, dated April 15, 2021, by and among mDR Limited and CHOO Chee Kong EX-10.16 18 ex10-16.htm Exhibit 10.16 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. 15 April 2021 CHOO CHEE KONG [*****] Dear Sir, PUT OPTION AGREEMENT 1. We refer to the Subscription Agreement dated |
|
| November 18, 2022 |
EX-10.3 5 ex10-3.htm Exhibit 10.3 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. LICENCE AGREEMENT This Agreement is made the first day of June 2018 between EXPLOIT TECHNOLOGIES PTE LTD (Co. Reg. No. 1 |
|
| November 18, 2022 |
EX-10.7 9 ex10-7.htm Exhibit 10.7 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. DATED the 16th day of December 2020 ACCELERATE TECHNOLOGIES PTE. LTD. AND CYTOMED THERAPEUTICS PTE LTD LICENCE AGREEMENT |
|
| November 18, 2022 |
Letter from Nexia TS Public Accounting Corporation EXHIBIT 16.1 U.S. Securities and Exchange Commission 100 F Street, N.E. Washington DC 20549 Dear Sir/Madam, We have read and are in agreement with the statements contained in the first four paragraphs under the heading ?Change in Registrant?s Certifying Accountant? contained in CytoMed Therapeutics Pte Ltd?s (?the Company?) Draft Registration Statement on Form F-1 dated September 30, 2022 confiden |
|
| November 18, 2022 |
Form of Consent of Dr. YEW Chak Hua EX-99.4 28 ex99-4.htm Exhibit 99.4 Consent to be Named as a Director Nominee In connection with the filing by CytoMed Therapeutics Pte. Ltd. of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board o |
|
| November 18, 2022 |
Calculation of Registration Fee EX-FILING FEES 35 ex107.htm Exhibit 107 Calculation of Filing Fee Tables Form F-1 (Form Type) CytoMed Therapeutics Pte. Ltd. (Exact Name of Registrant as Specified in its Charter) Not Applicable (Translation of Registrant’s Name into English) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered Proposed Maximum Offer |
|
| November 18, 2022 |
Form of Consent of WU Tao Thomas EX-99.6 30 ex99-6.htm Exhibit 99.6 Consent to be Named as a Director Nominee In connection with the filing by CytoMed Therapeutics Pte. Ltd. of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board o |
|
| November 18, 2022 |
Form of Consent of Dr. ZENG Jieming EX-99.1 25 ex99-1.htm Exhibit 99.1 Consent to be Named as a Director Nominee In connection with the filing by CytoMed Therapeutics Pte. Ltd. of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board o |
|
| November 18, 2022 |
EX-10.9 11 ex10-9.htm Exhibit 10.9 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. Landmark Medical Centre Sdn Bhd (Malaysian company with registration no. 350925H) Founding Shareholders And CytoMed The |
|
| November 18, 2022 |
EX-10.8 10 ex10-8.htm Exhibit 10.8 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. LICENCE AGREEMENT This Agreement is made the 31st. day of October 2020 between A*CCELERATE TECHNOLOGIES PTE LTD (Co. Re |
|
| November 18, 2022 |
EX-10.5 7 ex10-5.htm Exhibit 10.5 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. 23rd September 2021 Accelerate Technologies Pte Ltd 1, Fusionpolis Way, 19-00, Connexis North, Singapore 138632 Attentio |
|
| November 18, 2022 |
EX-10.6 8 ex10-6.htm Exhibit 10.6 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. 18 October 2022 Accelerate Technologies Pte Ltd 1, Fusionpolis Way, 19-00, Connexis North, Singapore 138632 Attention: C |
|
| November 18, 2022 |
Form of Audit Committee Charter EX-99.8 32 ex99-8.htm Exhibit 99.8 FORM OF AUDIT COMMITTEE CHARTER OF CYTOMED THERAPEUTICS PTE. LTD. Purpose The Audit Committee (the “Committee”) is appointed by the Board of Directors (the “Board”) of CytoMed Therapeutics Pte. Ltd. (the “Company”) to assist the Board in monitoring (1) the integrity of the annual and other financial statements of the Company, (2) the independent auditor’s qualifi |
|
| November 18, 2022 |
Form of Consent of Dr. TOH Keng Kiat EX-99.7 31 ex99-7.htm Exhibit 99.7 Consent to be Named as a Director Nominee In connection with the filing by CytoMed Therapeutics Pte. Ltd. of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board o |
|
| November 18, 2022 |
Letter in Lieu of Consent of WWC, P.C., an independent registered public accounting firm EX-15.1 21 ex15-1.htm EXHIBIT 15.1 To the Board of Directors and Shareholders of CytoMed Therapeutics Pte. Ltd LETTER IN LIEU OF CONSENT FOR REVIEW REPORT We have reviewed, in accordance with the standards of the Public Company Accounting Oversight Board (United States), the unaudited interim consolidated financial statements of CytoMed Therapeutics Pte. Ltd and its subsidiaries for the periods en |
|
| November 18, 2022 |
Exhibit 10.10 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. Schedule 2 Shareholders Agreement This Agreement (?Agreement?) is made on 20th January 2020 Between: (1) Landmark Medical Centre Sdn Bhd (re |
|
| November 18, 2022 |
Exhibit 10.14 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. DATED 10 DEC 2019 BETWEEN CYTOMED THERAPEUTICS PTE. LTD. (THE ?BORROWER?) AND MDR LIMITED (THE ?LENDER?) CONVERTIBLE LOAN AGREEMENT Dentons |
|
| November 18, 2022 |
List of Subsidiaries of the Registrant Exhibit 21.1 Subsidiary Jurisdiction of Incorporation CytoMed Therapeutics (Malaysia) Sdn. Bhd. Malaysia Advance Cancer Centre Pte. Ltd. Singapore Puricell Lab Pte. Ltd. Singapore IPSCBank Pte. Ltd. Singapore IPSC Depository Sdn. Bhd. Malaysia |
|
| November 18, 2022 |
Constitution of CytoMed Therapeutics Pte Ltd EX-3.1 2 ex3-1.htm Exhibit 3.1 Page 1 of 23 THE COMPANIES ACT (CHAPTER 50) A PRIVATE COMPANY LIMITED BY SHARES CONSTITUTION OF CYTOMED THERAPEUTICS PTE. LTD. 1. The name of the company is CYTOMED THERAPEUTICS PTE. LTD. 2. The registered office of the company is situated in the Republic of Singapore. 531A UPPER CROSS STREET #04- 95 HONG LIM COMPLEX Singapore 051531 3. The liability of the members i |
|
| November 18, 2022 |
Form of Consent of Prof. LOH Yuin Han EX-99.3 27 ex99-3.htm Exhibit 99.3 Consent to be Named as a Director Nominee In connection with the filing by CytoMed Therapeutics Pte. Ltd. of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board o |
|
| November 18, 2022 |
Title Deed (Subsidiary Strata Certificate of Title) Exhibit 10.17 |
|
| November 18, 2022 |
EX-10.2 4 ex10-2.htm Exhibit 10.2 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. SERVICE AGREEMENT This Service Agreement (“Agreement”) is made of and entered into on 08th September 2021 between CytoMe |
|
| November 18, 2022 |
Form of Consent of Dr. TAN Wee Kiat EX-99.2 26 ex99-2.htm Exhibit 99.2 Consent to be Named as a Director Nominee In connection with the filing by CytoMed Therapeutics Pte. Ltd. of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board o |
|
| November 18, 2022 |
Form of Consent of Mark LEONG Kei Wei EX-99.5 29 ex99-5.htm Exhibit 99.5 Consent to be Named as a Director Nominee In connection with the filing by CytoMed Therapeutics Pte. Ltd. of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board o |
|
| November 18, 2022 |
Exhibit 10.12 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. Date: 28th October 2021 To: Landmark Medical Centre Sdn. Bhd. BY HAND AND EMAIL ONLY Unit 33B, Menara Landmark No. 12, Jalan Ngee Heng 80000 |
|
| November 18, 2022 |
EX-10.15 17 ex10-15.htm Exhibit 10.15 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. dated 15 APRIL 2021 GLORIOUS FINANCE LIMITED (THE SUBSCRIBER) AND CYTOMED THERAPEUTICS PTE LTD (THE COMPANY) subscri |
|
| September 30, 2022 |
Exhibit 10.13 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. DATED 10 DEC 2019 BETWEEN CYTOMED THERAPEUTICS PTE. LTD. (THE ?BORROWER?) AND MDR LIMITED (THE ?LENDER?) CONVERTIBLE LOAN AGREEMENT Dentons |
|
| September 30, 2022 |
Consent to be Named as a Director Nominee Exhibit 99.3 Consent to be Named as a Director Nominee In connection with the filing by CytoMed Therapeutics Pte. Ltd. of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of CytoMed |
|
| September 30, 2022 |
Consent to be Named as a Director Nominee EX-99.7 25 filename25.htm Exhibit 99.7 Consent to be Named as a Director Nominee In connection with the filing by CytoMed Therapeutics Pte. Ltd. of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the boa |
|
| September 30, 2022 |
Consent to be Named as a Director Nominee EX-99.9 27 filename27.htm Exhibit 99.9 Consent to be Named as a Director Nominee In connection with the filing by CytoMed Therapeutics Pte. Ltd. of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the boa |
|
| September 30, 2022 |
Consent to be Named as a Director Nominee Exhibit 99.4 Consent to be Named as a Director Nominee In connection with the filing by CytoMed Therapeutics Pte. Ltd. of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of CytoMed |
|
| September 30, 2022 |
Consent to be Named as a Director Exhibit 99.2 Consent to be Named as a Director In connection with the filing by CytoMed Therapeutics Pte. Ltd. of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of CytoMed Therape |
|
| September 30, 2022 |
Consent to be Named as a Director Nominee Exhibit 99.6 Consent to be Named as a Director Nominee In connection with the filing by CytoMed Therapeutics Pte. Ltd. of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of CytoMed |
|
| September 30, 2022 |
EX-10.15 16 filename16.htm Exhibit 10.15 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. 15 April 2021 CHOO CHEE KONG [*****] Dear Sir, PUT OPTION AGREEMENT 1. We refer to the Subscription Agreement dat |
|
| September 30, 2022 |
CytoMed Therapeutics Pte. Ltd. 2022 EQUITY INCENTIVE PLAN Exhibit 10.1 CytoMed Therapeutics Pte. Ltd. 2022 EQUITY INCENTIVE PLAN 1. Purpose. The purposes of this Plan are: (a) to attract and retain the best available personnel for positions of substantial responsibility, (b) to provide additional incentives to Employees, Directors, and Consultants (including members of the Company?s Scientific Advisory Board), and (c) to promote the success of the Compan |
|
| September 30, 2022 |
EX-10.3 4 filename4.htm Exhibit 10.3 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. LICENCE AGREEMENT This Agreement is made the first day of June 2018 between EXPLOIT TECHNOLOGIES PTE LTD (Co. Reg. No |
|
| September 30, 2022 |
Consent to be Named as a Director Nominee EX-99.8 26 filename26.htm Exhibit 99.8 Consent to be Named as a Director Nominee In connection with the filing by CytoMed Therapeutics Pte. Ltd. of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the boa |
|
| September 30, 2022 |
EX-10.7 8 filename8.htm Exhibit 10.7 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. LICENCE AGREEMENT This Agreement is made the 31st. day of October 2020 between A*CCELERATE TECHNOLOGIES PTE LTD (Co. |
|
| September 30, 2022 |
Exhibit 10.6 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. DATED the 16th day of December 2020 ACCELERATE TECHNOLOGIES PTE. LTD. AND CYTOMED THERAPEUTICS PTE LTD LICENCE AGREEMENT [*****] ACCELERATE-C |
|
| September 30, 2022 |
Exhibit 10.12 |
|
| September 30, 2022 |
This is a confidential draft submission to the U.S. Securities and Exchange Commission pursuant to Section 106(a) of the Jumpstart Our Business Startups Act of 2012, submitted on September 30, 2022, as Amendment No. 3 to the confidential submission dated December 17, 2021, and is not being filed publicly under the Securities Act of 1933, as amended. All information herein remains strictly confiden |
|
| September 30, 2022 |
Schedule 2 Shareholders Agreement Exhibit 10.9 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. Schedule 2 Shareholders Agreement This Agreement (?Agreement?) is made on 20th January 2020 Between: (1) Landmark Medical Centre Sdn Bhd (reg |
|
| September 30, 2022 |
Exhibit 10.11 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. Date: 28th October 2021 To: Landmark Medical Centre Sdn. Bhd. BY HAND AND EMAIL ONLY Unit 33B, Menara Landmark No. 12, Jalan Ngee Heng 80000 |
|
| September 30, 2022 |
Consent to be Named as a Director Nominee Exhibit 99.5 Consent to be Named as a Director Nominee In connection with the filing by CytoMed Therapeutics Pte. Ltd. of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of CytoMed |
|
| September 30, 2022 |
Exhibit 10.2 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. SERVICE AGREEMENT This Service Agreement (?Agreement?) is made of and entered into on 08th September 2021 between CytoMed Therapeutics (Malay |
|
| September 30, 2022 |
EX-10.5 6 filename6.htm Exhibit 10.5 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. 23rd September 2021 Accelerate Technologies Pte Ltd 1, Fusionpolis Way, 19-00, Connexis North, Singapore 138632 Atten |
|
| September 30, 2022 |
Exhibit 10.8 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. Landmark Medical Centre Sdn Bhd (Malaysian company with registration no. 350925H) Founding Shareholders And CytoMed Therapeutics Pte Ltd (Sin |
|
| September 30, 2022 |
U.S. Securities and Exchange Commission EXHIBIT 16.1 U.S. Securities and Exchange Commission 100 F Street, N.E. Washington DC 20549 Dear Sir/Madam, We have read and are in agreement with the statements contained in the first four paragraphs under the heading ?Change in Registrant?s Certifying Accountant? contained in CytoMed Therapeutics Pte Ltd?s (?the Company?) Draft Registration Statement on Form F-1 dated September 30, 2022 confiden |
|
| September 30, 2022 |
Exhibit 10.10 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. THIS SUPPLEMENTAL AGREEMENT is made on 20 January 2021 BETWEEN: (1) Landmark Medical Centre Sdn Bhd (registration no. 350925H) a company inc |
|
| September 30, 2022 |
Exhibit 10.14 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) the type that the registrant treats as private or confidential. dated 15 APRIL 2021 GLORIOUS FINANCE LIMITED (THE SUBSCRIBER) AND CYTOMED THERAPEUTICS PTE LTD (THE COMPANY) subscription agreement Relating |
|
| September 30, 2022 |
Consent to be Named as a Director Exhibit 99.1 Consent to be Named as a Director In connection with the filing by CytoMed Therapeutics Pte. Ltd. of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of CytoMed Therape |
|
| September 30, 2022 |
Exhibit 10.16 |
|
| September 30, 2022 |
Exhibit 10.4 ADDENDUM TO LICENCE AGREEMENT THIS AGREEMENT is made the 1st day of Dec 2020 (?Effective Date?) Between ACCELERATE TECHNOLOGIES PTE LTD, f.k.a.EXPLOIT TECHNOLOGIES PTE LTD (Co. Reg. No. 1995053187D), a company incorporated in Singapore and having its place of business at 1 Fusionopolis Way, #19-00 Connexis North, Singapore 138632 (hereinafter referred to as ?A*ccelerate?) ; and An CYT |
|
| January 18, 2022 |
CytoMed Therapeutics Pte. Ltd. 1 Commonwealth Lane Singapore 149544 +65 6250 7738 CytoMed Therapeutics Pte. Ltd. 1 Commonwealth Lane #08-22 Singapore 149544 +65 6250 7738 VIA EDGAR January 18, 2022 U.S. Securities & Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attn: Tracie Mariner Re: CytoMed Therapeutics Pte. Ltd. Amendment No. 2 to Draft Registration Statement on Form F-1 Submitted December 20, 2021 CIK No |
|
| December 20, 2021 |
Exhibit 10.14 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. dated 15 APRIL 2021 GLORIOUS FINANCE LIMITED (THE SUBSCRIBER) AND CYTOMED THERAPEUTICS PTE LTD (THE COMPANY) subscription agreement Relating to shares |
|
| December 20, 2021 |
DRS/A 1 filename1.htm This is a confidential draft submission to the U.S. Securities and Exchange Commission pursuant to Section 106(a) of the Jumpstart Our Business Startups Act of 2012, submitted on December 17, 2021, as Amendment No. 2 to the confidential submission dated September 28, 2021, and is not being filed publicly under the Securities Act of 1933, as amended. All information herein rem |
|
| December 17, 2021 |
CytoMed Therapeutics Pte. Ltd. 21 Bukit Batok Crescent #17-80 WCEGA Tower Singapore 658065 DRSLTR 1 filename1.htm CytoMed Therapeutics Pte. Ltd. 21 Bukit Batok Crescent #17-80 WCEGA Tower Singapore 658065 VIA EDGAR December 17, 2021 U.S. Securities & Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attn: Tracie Mariner Re: CytoMed Therapeutics Pte. Ltd. Amendment No. 1 to Draft Registration Statement on Form F-1 Submitte |
|
| November 19, 2021 |
Exhibit 21.1 Subsidiary Jurisdiction of Incorporation CytoMed Therapeutics (Malaysia) Sdn. Bhd. Malaysia Advance Cancer Centre Pte. Ltd. Singapore Puricell Lab Pte. Ltd. Singapore IPSCBank Pte. Ltd. Singapore IPSC Depository Sdn. Bhd. Malaysia |
|
| November 19, 2021 |
Form of Consent to be Named as a Director Nominee EX-99.9 22 filename22.htm Exhibit 99.9 Form of Consent to be Named as a Director Nominee In connection with the filing by CytoMed Therapeutics Pte. Ltd. of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to |
|
| November 19, 2021 |
CODE OF BUSINESS CONDUCT AND ETHICS EX-99.13 26 filename26.htm Exhibit 99.13 CODE OF BUSINESS CONDUCT AND ETHICS 1. Introduction The Board of Directors of CytoMed Therapeutics Pte. Ltd. has adopted this code of business conduct and ethics (the “Code”), which is applicable to all directors, officers and employees, to: ● promote honest and ethical conduct, including the ethical handling of actual or apparent conflicts of interest betw |
|
| November 19, 2021 |
EX-10.5 6 filename6.htm Exhibit 10.5 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. 23rd September 2021 Accelerate Technologies Pte Ltd 1, Fusionpolis Way, 19-00, Connexis North, Singapore 138632 Attention: Comm |
|
| November 19, 2021 |
FORM OF NOMINATING AND CORPORATE GOVERNANCE COMMITTEE CHARTER CYTOMED THERAPEUTICS PTE. LTD. Exhibit 99.12 FORM OF NOMINATING AND CORPORATE GOVERNANCE COMMITTEE CHARTER OF CYTOMED THERAPEUTICS PTE. LTD. The responsibilities and powers of this Nominating and Corporate Governance Committee (the ?Committee?) as delegated by the Board of Directors (the ?Board?) of CytoMed Therapeutics Pte. Ltd. (the ?Company?) are set forth in this charter. Whenever the Committee takes an action, it shall exe |
|
| November 19, 2021 |
Form of Consent to be Named as a Director Nominee Exhibit 99.4 Form of Consent to be Named as a Director Nominee In connection with the filing by CytoMed Therapeutics Pte. Ltd. of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of |
|
| November 19, 2021 |
Form of Consent to be Named as a Director Nominee Exhibit 99.6 Form of Consent to be Named as a Director Nominee In connection with the filing by CytoMed Therapeutics Pte. Ltd. of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of |
|
| November 19, 2021 |
FORM OF AUDIT COMMITTEE CHARTER CYTOMED THERAPEUTICS PTE. LTD. EX-99.10 23 filename23.htm Exhibit 99.10 FORM OF AUDIT COMMITTEE CHARTER OF CYTOMED THERAPEUTICS PTE. LTD. Purpose The Audit Committee (the “Committee”) is appointed by the Board of Directors (the “Board”) of CytoMed Therapeutics Pte. Ltd. (the “Company”) to assist the Board in monitoring (1) the integrity of the annual and other financial statements of the Company, (2) the independent auditor’s q |
|
| November 19, 2021 |
FORM OF COMPENSATION COMMITTEE CHARTER CYTOMED THERAPEUTICS PTE. LTD. EX-99.11 24 filename24.htm Exhibit 99.11 FORM OF COMPENSATION COMMITTEE CHARTER OF CYTOMED THERAPEUTICS PTE. LTD. I. PURPOSES The Compensation Committee (the “Committee”) is appointed by the Board of Directors (the “Board”) of CytoMed Therapeutics Pte. Ltd. (the “Company”) for the purposes of, among other things, (a) discharging the Board’s responsibilities relating to the compensation of the Comp |
|
| November 19, 2021 |
EX-10.14 11 filename11.htm Exhibit 10.14 dated (THE SUBSCRIBER) AND CYTOMED THERAPEUTICS PTE LTD (THE COMPANY) subscription agreement Relating to shares in the capital of CYTOMED THERAPEUTICS PTE LTD Confidential THIS subscription agreement (“Agreement”) is made on BETWEEN: 1. (the “Subscriber”); and 2. CytoMed Therapeutics Pte Ltd (Company No. 201808327H) a company incorporated in, and existing u |
|
| November 19, 2021 |
EX-10.6 7 filename7.htm Exhibit 10.6 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. DATED the 16th day of December 2020 ACCELERATE TECHNOLOGIES PTE. LTD. AND CYTOMED THERAPEUTICS PTE LTD LICENCE AGREEMENT [***** |
|
| November 19, 2021 |
Exhibit 10.4 ADDENDUM TO LICENCE AGREEMENT THIS AGREEMENT is made the 1st day of Dec 2020 (?Effective Date?) Between ACCELERATE TECHNOLOGIES PTE LTD, f.k.a.EXPLOIT TECHNOLOGIES PTE LTD (Co. Reg. No. 1995053187D), a company incorporated in Singapore and having its place of business at 1 Fusionopolis Way, #19-00 Connexis North, Singapore 138632 (hereinafter referred to as ?A*ccelerate?) ; and An CYT |
|
| November 19, 2021 |
Schedule 2 Shareholders Agreement EX-10.9 9 filename9.htm Exhibit 10.9 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. Schedule 2 Shareholders Agreement This Agreement (“Agreement”) is made on 20th January 2020 Between: (1) Landmark Medical Centr |
|
| November 19, 2021 |
Form of Consent to be Named as a Director Nominee Exhibit 99.3 Form of Consent to be Named as a Director Nominee In connection with the filing by CytoMed Therapeutics Pte. Ltd. of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the ?Securities Act?), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the board of directors of |
|
| November 19, 2021 |
This is a confidential draft submission to the U.S. Securities and Exchange Commission pursuant to Section 106(a) of the Jumpstart Our Business Startups Act of 2012, submitted on November 19, 2021, as Amendment No.1 to the confidential submission dated September 28, 2021, and is not being filed publicly under the Securities Act of 1933, as amended. All information herein remains strictly confident |
|
| November 19, 2021 |
Exhibit 10.3 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. LICENCE AGREEMENT This Agreement is made the first day of June 2018 between EXPLOIT TECHNOLOGIES PTE LTD (Co. Reg. No. 199503187D), a company incorpora |
|
| November 19, 2021 |
Exhibit 10.13 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. DATED 10 DEC 2019 BETWEEN CYTOMED THERAPEUTICS PTE. LTD. (THE ?BORROWER?) AND MDR LIMITED (THE ?LENDER?) CONVERTIBLE LOAN AGREEMENT Dentons Rodyk & Da |
|
| November 19, 2021 |
CytoMed Therapeutics Pte. Ltd. 21 Bukit Batok Crescent #17-80 WCEGA Tower Singapore 658065 DRSLTR 1 filename1.htm CytoMed Therapeutics Pte. Ltd. 21 Bukit Batok Crescent #17-80 WCEGA Tower Singapore 658065 VIA EDGAR November 19, 2021 U.S. Securities & Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, NE Washington, D.C. 20549 Attn: Tracie Mariner Re: CytoMed Therapeutics Pte. Ltd. Draft Registration Statement on Form F-1 Submitted September 28, 202 |
|
| November 19, 2021 |
Form of Consent to be Named as a Director Nominee EX-99.5 18 filename18.htm Exhibit 99.5 Form of Consent to be Named as a Director Nominee In connection with the filing by CytoMed Therapeutics Pte. Ltd. of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to |
|
| November 19, 2021 |
Form of Consent to be Named as a Director Nominee EX-99.8 21 filename21.htm Exhibit 99.8 Form of Consent to be Named as a Director Nominee In connection with the filing by CytoMed Therapeutics Pte. Ltd. of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to |
|
| November 19, 2021 |
Form of Consent to be Named as a Director EX-99.2 15 filename15.htm Exhibit 99.2 Form of Consent to be Named as a Director In connection with the filing by CytoMed Therapeutics Pte. Ltd. of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the boa |
|
| November 19, 2021 |
Form of Consent to be Named as a Director EX-99.1 14 filename14.htm Exhibit 99.1 Form of Consent to be Named as a Director In connection with the filing by CytoMed Therapeutics Pte. Ltd. of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the boa |
|
| November 19, 2021 |
EX-3.1 2 filename2.htm Exhibit 3.1 Page 1 of 23 THE COMPANIES ACT (CHAPTER 50) A PRIVATE COMPANY LIMITED BY SHARES CONSTITUTION OF CYTOMED THERAPEUTICS PTE. LTD. 1. The name of the company is CYTOMED THERAPEUTICS PTE. LTD. 2. The registered office of the company is situated in the Republic of Singapore. 531A UPPER CROSS STREET #04- 95 HONG LIM COMPLEX Singapore 051531 3. The liability of the membe |
|
| November 19, 2021 |
EX-10.2 3 filename3.htm Exhibit 10.2 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. SERVICE AGREEMENT This Service Agreement (“Agreement”) is made of and entered into on 08th September 2021 between CytoMed Thera |
|
| November 19, 2021 |
EX-10.15 12 filename12.htm Exhibit 10.15 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. 15 April 2021 CHOO CHEE KONG [*****] Dear Sir, PUT OPTION AGREEMENT 1. We refer to the Subscription Agreement dated 15 Apri |
|
| November 19, 2021 |
EX-10.7 8 filename8.htm Exhibit 10.7 Pursuant to Item 601(b)(10)(iv) of Regulation S-K, certain identified information marked with [*****] has been excluded from the exhibit because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed. LICENCE AGREEMENT This Agreement is made the 31st. day of October 2020 between ETPL TECHNOLOGIES PTE LTD (Co. Reg. No. 19950318 |
|
| November 19, 2021 |
Form of Consent to be Named as a Director EX-99.7 20 filename20.htm Exhibit 99.7 Form of Consent to be Named as a Director In connection with the filing by CytoMed Therapeutics Pte. Ltd. of the Registration Statement on Form F-1 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named as a nominee to the boa |
|
| September 28, 2021 |
DRS 1 filename1.htm This is a confidential draft submission to the U.S. Securities and Exchange Commission pursuant to Section 106(a) of the Jumpstart Our Business Startups Act of 2012, submitted on September 28, 2021, and is not being filed publicly under the Securities Act of 1933, as amended. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM F-1 |
